Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -67.8 Million USD | -580.85% |
| 2021 | 14.1 Million USD | 111.43% |
| 2020 | -123.4 Million USD | -243.32% |
| 2019 | 86.1 Million USD | 0.0% |
| 2018 | 86.1 Million USD | -24.01% |
| 2017 | 113.3 Million USD | 17.53% |
| 2016 | 96.4 Million USD | -50.18% |
| 2015 | 193.5 Million USD | 21.55% |
| 2014 | 159.2 Million USD | -41.99% |
| 2013 | 274.44 Million USD | 20.37% |
| 2012 | 228 Million USD | 26.44% |
| 2011 | 180.31 Million USD | 14.03% |
| 2010 | 158.13 Million USD | 17.15% |
| 2009 | 134.97 Million USD | -2.48% |
| 2008 | 138.4 Million USD | 175.71% |
| 2007 | 50.19 Million USD | 222.93% |
| 2006 | -40.83 Million USD | -5.46% |
| 2005 | -38.72 Million USD | -18.7% |
| 2004 | -32.62 Million USD | 11.5% |
| 2003 | -36.85 Million USD | -66.71% |
| 2002 | -22.1 Million USD | -58.5% |
| 2001 | -13.94 Million USD | -53.24% |
| 2000 | -9.1 Million USD | -15.53% |
| 1999 | -7.87 Million USD | 14.36% |
| 1998 | -9.2 Million USD | 28.68% |
| 1997 | -12.9 Million USD | 3.01% |
| 1996 | -13.3 Million USD | -27.88% |
| 1995 | -10.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -32.7 Million USD | -4.47% |
| 2023 Q3 | -46.1 Million USD | 54.94% |
| 2023 Q2 | -102.3 Million USD | -212.84% |
| 2022 Q4 | -31.3 Million USD | -3.3% |
| 2022 Q3 | -30.3 Million USD | -588.64% |
| 2022 Q2 | -4.4 Million USD | -144.44% |
| 2022 Q1 | -1.8 Million USD | 93.94% |
| 2022 FY | - USD | -580.85% |
| 2021 Q4 | -29.7 Million USD | -153.51% |
| 2021 Q2 | 17.3 Million USD | 163.37% |
| 2021 Q1 | -27.3 Million USD | 43.36% |
| 2021 FY | - USD | 111.43% |
| 2021 Q3 | 55.5 Million USD | 220.81% |
| 2020 Q3 | -24.2 Million USD | 35.81% |
| 2020 FY | - USD | -243.32% |
| 2020 Q2 | -37.7 Million USD | -137.11% |
| 2020 Q1 | -15.9 Million USD | -272.83% |
| 2020 Q4 | -48.2 Million USD | -99.17% |
| 2019 Q1 | 24.8 Million USD | -4.62% |
| 2019 Q2 | -4.8 Million USD | -119.35% |
| 2019 Q3 | -500 Thousand USD | 89.58% |
| 2019 Q4 | 9.2 Million USD | 1940.0% |
| 2019 FY | - USD | 0.0% |
| 2018 Q2 | 32.5 Million USD | 12.85% |
| 2018 Q4 | 26 Million USD | 19.82% |
| 2018 FY | - USD | -24.01% |
| 2018 Q1 | 28.8 Million USD | -5.57% |
| 2018 Q3 | 21.7 Million USD | -33.23% |
| 2017 Q1 | 27.6 Million USD | 87.76% |
| 2017 Q4 | 30.5 Million USD | 10.91% |
| 2017 FY | - USD | 17.53% |
| 2017 Q3 | 27.5 Million USD | -10.13% |
| 2017 Q2 | 30.6 Million USD | 10.87% |
| 2016 Q4 | 14.7 Million USD | -4.55% |
| 2016 Q2 | 35.7 Million USD | -27.29% |
| 2016 Q1 | 49.1 Million USD | -5.39% |
| 2016 FY | - USD | -50.18% |
| 2016 Q3 | 15.4 Million USD | -56.86% |
| 2015 Q3 | 50.1 Million USD | 38.4% |
| 2015 FY | - USD | 21.55% |
| 2015 Q1 | 35.74 Million USD | -1.66% |
| 2015 Q2 | 36.2 Million USD | 1.29% |
| 2015 Q4 | 51.9 Million USD | 3.59% |
| 2014 Q3 | 25.92 Million USD | -51.32% |
| 2014 Q4 | 36.34 Million USD | 40.21% |
| 2014 FY | - USD | -41.99% |
| 2014 Q1 | 55.28 Million USD | -33.39% |
| 2014 Q2 | 53.25 Million USD | -3.68% |
| 2013 Q2 | 65.91 Million USD | 13.81% |
| 2013 Q1 | 57.91 Million USD | 4.2% |
| 2013 FY | - USD | 20.37% |
| 2013 Q4 | 82.99 Million USD | 0.11% |
| 2013 Q3 | 82.9 Million USD | 25.77% |
| 2012 FY | - USD | 26.44% |
| 2012 Q1 | 46.09 Million USD | 1.23% |
| 2012 Q4 | 55.58 Million USD | 14.42% |
| 2012 Q3 | 48.58 Million USD | 2.74% |
| 2012 Q2 | 47.28 Million USD | 2.59% |
| 2011 Q2 | 43.73 Million USD | 4.42% |
| 2011 Q4 | 45.52 Million USD | 9.41% |
| 2011 FY | - USD | 14.03% |
| 2011 Q1 | 41.88 Million USD | 8.32% |
| 2011 Q3 | 41.61 Million USD | -4.85% |
| 2010 FY | - USD | 17.15% |
| 2010 Q3 | 35.72 Million USD | -9.33% |
| 2010 Q2 | 39.4 Million USD | 18.67% |
| 2010 Q1 | 33.2 Million USD | -3.02% |
| 2010 Q4 | 38.66 Million USD | 8.23% |
| 2009 Q1 | 24.75 Million USD | 23.07% |
| 2009 Q4 | 34.23 Million USD | 7.98% |
| 2009 Q3 | 31.7 Million USD | -58.26% |
| 2009 Q2 | 75.96 Million USD | 206.91% |
| 2009 FY | - USD | -2.48% |
| 2008 Q1 | -5.46 Million USD | 16.85% |
| 2008 FY | - USD | 175.71% |
| 2008 Q4 | 20.11 Million USD | 14.45% |
| 2008 Q3 | 17.57 Million USD | -75.41% |
| 2008 Q2 | 71.47 Million USD | 1408.07% |
| 2007 Q3 | -9.24 Million USD | 15.28% |
| 2007 Q2 | -10.9 Million USD | -52.13% |
| 2007 Q1 | -7.16 Million USD | -154.34% |
| 2007 FY | - USD | 222.93% |
| 2007 Q4 | -6.57 Million USD | 28.89% |
| 2006 Q2 | -12.18 Million USD | -19.35% |
| 2006 Q1 | -10.21 Million USD | -29.15% |
| 2006 FY | - USD | -5.46% |
| 2006 Q4 | 13.19 Million USD | 199.83% |
| 2006 Q3 | -13.21 Million USD | -8.43% |
| 2005 Q4 | -7.9 Million USD | 5.97% |
| 2005 FY | - USD | -18.7% |
| 2005 Q2 | -5.23 Million USD | 43.07% |
| 2005 Q1 | -9.18 Million USD | -1.18% |
| 2005 Q3 | -8.41 Million USD | -60.8% |
| 2004 Q2 | -9.46 Million USD | 2.45% |
| 2004 Q1 | -9.7 Million USD | -8.5% |
| 2004 Q3 | -9.12 Million USD | 3.63% |
| 2004 Q4 | -9.08 Million USD | 0.48% |
| 2004 FY | - USD | 11.5% |
| 2003 Q1 | -4.81 Million USD | 21.08% |
| 2003 Q2 | -6.37 Million USD | -32.23% |
| 2003 Q3 | -8.73 Million USD | -37.17% |
| 2003 FY | - USD | -66.71% |
| 2003 Q4 | -8.94 Million USD | -2.37% |
| 2002 Q4 | -6.1 Million USD | -26.79% |
| 2002 FY | - USD | -58.5% |
| 2002 Q3 | -4.81 Million USD | 20.18% |
| 2002 Q2 | -6.03 Million USD | -86.89% |
| 2002 Q1 | -3.22 Million USD | -15.81% |
| 2001 Q4 | -2.78 Million USD | -46.6% |
| 2001 FY | - USD | -53.24% |
| 2001 Q1 | -2.27 Million USD | 1.18% |
| 2001 Q2 | -2.43 Million USD | -7.41% |
| 2001 Q3 | -1.9 Million USD | 22.06% |
| 2000 FY | - USD | -15.53% |
| 2000 Q4 | -2.29 Million USD | -9.78% |
| 2000 Q1 | -2.22 Million USD | -71.38% |
| 2000 Q2 | -2.59 Million USD | -16.33% |
| 2000 Q3 | -2.09 Million USD | 19.22% |
| 1999 Q2 | -2.3 Million USD | 4.17% |
| 1999 Q1 | -2.4 Million USD | 25.0% |
| 1999 FY | - USD | 14.36% |
| 1999 Q4 | -1.3 Million USD | 27.78% |
| 1999 Q3 | -1.8 Million USD | 21.74% |
| 1998 Q4 | -3.2 Million USD | 3.03% |
| 1998 FY | - USD | 28.68% |
| 1998 Q1 | -3.5 Million USD | -12.9% |
| 1998 Q2 | -3.6 Million USD | -2.86% |
| 1998 Q3 | -3.3 Million USD | 8.33% |
| 1997 Q1 | -4.1 Million USD | 10.87% |
| 1997 Q2 | -600 Thousand USD | 85.37% |
| 1997 Q3 | -2.8 Million USD | -366.67% |
| 1997 FY | - USD | 3.01% |
| 1997 Q4 | -3.1 Million USD | -10.71% |
| 1996 Q3 | -4 Million USD | -14.29% |
| 1996 FY | - USD | -27.88% |
| 1996 Q1 | -3.3 Million USD | -26.92% |
| 1996 Q4 | -4.6 Million USD | -15.0% |
| 1996 Q2 | -3.5 Million USD | -6.06% |
| 1995 Q4 | -2.6 Million USD | -360.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 58.435% |
| Dynavax Technologies Corporation | 9.66 Million USD | 801.428% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 168.999% |
| Perrigo Company plc | 646.2 Million USD | 110.492% |
| Illumina, Inc. | -608 Million USD | 88.849% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.628% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 84.9% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.399% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.082% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 34.677% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.457% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -81.852% |
| Waters Corporation | 1.02 Billion USD | 106.632% |
| Biogen Inc. | 2.37 Billion USD | 102.852% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 22.45% |
| Evolus, Inc. | -41.81 Million USD | -62.162% |
| Adicet Bio, Inc. | -136.53 Million USD | 50.342% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 42.371% |
| bluebird bio, Inc. | -167.16 Million USD | 59.44% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 54.833% |
| FibroGen, Inc. | -261.4 Million USD | 74.063% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 104.043% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -52.577% |
| Homology Medicines, Inc. | -47.75 Million USD | -41.972% |
| Geron Corporation | -174.78 Million USD | 61.209% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 70.279% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 26.368% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 32.756% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 86.609% |
| Zoetis Inc. | 3.68 Billion USD | 101.84% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -34.066% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 105.825% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 121.851% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.472% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -87.905% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 70.523% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 74.511% |
| Verastem, Inc. | -83.16 Million USD | 18.476% |
| Nektar Therapeutics | -243.1 Million USD | 72.111% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 69.865% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 22.941% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 84.563% |
| OPKO Health, Inc. | -65.51 Million USD | -3.486% |
| Exelixis, Inc. | 196.6 Million USD | 134.486% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 116.294% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 162.59% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -21.601% |
| uniQure N.V. | -253.1 Million USD | 73.212% |
| Imunon, Inc. | -20.78 Million USD | -226.24% |
| Blueprint Medicines Corporation | -474.61 Million USD | 85.715% |
| Insmed Incorporated | -654.73 Million USD | 89.645% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 115.002% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 80.374% |
| TG Therapeutics, Inc. | 26.1 Million USD | 359.77% |
| Incyte Corporation | 919.42 Million USD | 107.374% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 86.582% |